Most important in brief
- An EGFR change arises in the tumour. It is usually not inherited.
- In Europe about 1 in 7 people with NSCLC have it, more often people who never smoked.
- The first treatment is usually a targeted tablet, alone or combined.
- Which form your report shows (e.g. exon 19, L858R, exon 20) matters for the choice.
What does EGFR mean?
EGFR is a gene. It holds the instructions for a kind of antenna on the cell that receives growth signals. With an EGFR change (mutation) in the tumour, this antenna keeps sending the “grow” signal, even when it should not.
The change arises in the tumour itself. It is usually not inherited. The good news: for EGFR changes there have been tablets for many years that block exactly this signal.
How common is it?
In European studies, on average about 14 in every 100 people with NSCLC had an EGFR change, and about 38 in 100 in Asian studies (Zhang et al., Oncotarget 2016).
It is more common in adenocarcinoma, in women and in people who never smoked. It also occurs in smokers, which is why every advanced NSCLC is tested for it (ESMO).
Which form does your report show?
There are different EGFR changes. Your report says which one it is, and this matters for the choice of treatment.
| On the report | What it is | What it can mean |
|---|---|---|
| Exon 19 deletion (ex19del) | The most common form | A “classic” change. EGFR tablets usually work well. |
| L858R (exon 21) | The second most common form | Also “classic”. EGFR tablets usually work well. |
| Exon 20 insertion | Less common | The usual tablets hardly work. There is a separate treatment with an antibody. |
| Uncommon forms, e.g. G719X, L861Q, S768I | Rare | Some tablets work; the choice is individual. |
The first treatment for advanced disease
With the classic forms, the first treatment is almost always targeted, not chemotherapy or immunotherapy alone. Options authorised in the EU include:
| Option | When it is often chosen |
|---|---|
| Osimertinib (tablet) alone | The most common standard. Also works well in the brain (EMA). |
| Osimertinib with chemotherapy | On average holds the disease back longer, but is more demanding. Often with extensive disease (EU approval 2024). |
| Amivantamab (infusion) with lazertinib (tablet) | Another combination, also working longer than osimertinib alone, with more skin and infusion side effects (EU approval; EMA). |
| Older EGFR tablets | e.g. afatinib, dacomitinib, erlotinib, gefitinib. Still used, for example when osimertinib is not available. |
| For exon 20 insertion: amivantamab with chemotherapy | The usual first treatment for this form (EMA). |
Immunotherapy alone usually helps less with EGFR changes than in other forms of lung cancer (ESMO). Discuss with your care team which option fits you and what is available in your country.
In earlier stages
Even after the tumour has been removed by surgery or treated with chemoradiotherapy, an EGFR tablet afterwards can lower the risk of the cancer coming back.
Osimertinib is authorised for this in the EU (EMA). That is why the EGFR test matters in earlier stages too.
Before surgery, with EGFR, chemotherapy without immunotherapy is usually given, such as cisplatin or carboplatin with pemetrexed. Immunotherapy helps less with EGFR.
When the first treatment stops working
After months or years, the tumour often finds a way around the tablet. A new sample, from tissue or blood, is then often tested to see what has changed.
- Amivantamab with chemotherapy, authorised in the EU after osimertinib (EU approval).
- Platinum chemotherapy, often with pemetrexed.
- Osimertinib, if an older tablet was given first and the new test shows the T790M change.
- Clinical trial: new medicines are being tested after EGFR tablets.
Living with the tablets
Common side effects are rash, dry skin, diarrhoea and inflamed nail beds. They can usually be treated well if you talk about them early. Amivantamab infusions can cause reactions, so they are given slowly and under supervision at first (EMA; EMA).
Questions about EGFR
Why ask?
The exact form, such as exon 19 or L858R, decides which tablet fits.
Why ask?
There are several approaches with different burdens.
Why ask?
This differs from country to country.
Why ask?
With EGFR the cancer spreads to the brain more often; regular checks find spots early.
Why ask?
A new test shows why the tablet stopped working and what fits next.
Sources
- ESMO Living Guideline: oncogene-addicted metastatic NSCLC
- Onkopedia: Lungenkarzinom, nicht-kleinzellig (NSCLC)
- Zhang et al., Oncotarget 2016: prevalence of EGFR mutations in NSCLC (meta-analysis)
- EMA: EPAR osimertinib
- EMA: EPAR amivantamab
- EMA: EPAR lazertinib
- EMA, CHMP opinion of 30 May 2024: osimertinib with pemetrexed and platinum chemotherapy
- EMA, CHMP opinion of 14 November 2024: amivantamab with lazertinib
- EMA, CHMP opinion of 25 July 2024: amivantamab with carboplatin and pemetrexed after an EGFR tablet